Bach launches tool linking cancer drug prices to value

Peter Bach, director of the Center for Health Policy Outcomes at Memorial Sloan Kettering Cancer Center (MSKCC), launched an interactive tool that compares the value-based price of a cancer drug with its market price. The tool, called (see BioCentury Extra, Oct. 3, 2014).

Bach worked with reimbursement consultancy Real Endpoints LLC to develop DrugAbacus. Roger Longman, CEO of Real Endpoints, told BioCentury "drug companies in particular should be thinking about how they demonstrate value within their product development programs and how they communicate it." ...